Skip to main
AFMD
AFMD logo

Affimed (AFMD) Stock Forecast & Price Target

Affimed (AFMD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 44%
Hold 19%
Sell 0%
Strong Sell 0%

Bulls say

Affimed NV's positive outlook is supported by a decrease in operating expenses, leading to increased earnings per share (EPS) estimates for 2025, and an improved probability of success (PoS) for the AFM13 combination therapy in Hodgkin lymphoma, which was raised from 70% to 80%. The company is generating promising results with its AFM24 and AFM28 therapies, where AFM28 has exhibited the highest complete response (CR) and complete response with incomplete recovery (CRi) rates among anti-CD123 therapies, indicating its potential for market leadership. Additionally, the favorable safety and tolerability profile of AFM28 positions it as a viable combination therapy in the refractory/relapsed setting, further enhancing its attractiveness to potential partners for commercialization.

Bears say

Affimed NV, a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, reported total revenues of only €0.2 million for the third quarter of 2024, significantly lower than the consensus estimate of €1.5 million. Furthermore, the company faced a net loss of €0.94 per share, which is slightly higher than the consensus loss estimate of €0.92 per share, indicating ongoing financial challenges. Additionally, with only €48.5 million in cash as of March 31, 2024, and a guided cash runway into the second half of 2025, the company is at risk of potential financing issues that could hinder its operational capabilities and development timeline.

Affimed (AFMD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 44% recommend Buy, 19% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Affimed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Affimed (AFMD) Forecast

Analysts have given Affimed (AFMD) a Buy based on their latest research and market trends.

According to 16 analysts, Affimed (AFMD) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Affimed (AFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.